Encore Medical Education announces publication of the Official Best of SABCS® News Highlights summarizing key trial results from the 2022 SABCS®
Best of SABCS® News Highlights coverage will provide daily expert video summaries along with original presentation slides of the most significant breast cancer trials for oncologists worldwide. SAN ANTONIO, Dec. 1, 2022 /PRNewswire/ -- Encore Medical Education, a US-based medical education company will launch the 2022 edition of the Best of SABCS®...
SK Biopharmaceuticals Names Donghoon Lee, Head of Bio Investment Center of SK Inc., as New CEO
Mr. Lee brings expertise in global new biz development to further strengthen SK Biopharmaceuticals as SK Group's key bio business PANGYO, South Korea, Nov. 30, 2022 /PRNewswire/ -- SK Biopharmaceuticals, an innovative global pharmaceutical company, announced that it has named Mr. Donghoon Lee, Executive Vice President and Head of Bio Investment Center...
New CRISPR/Cas9 license agreement for ERS Genomics and Cosmo Bio
Return to the index page SQL ERROR Can't connect to MySQL server on '192.168.120.250' (111) An sql error occurred while fetching this page. Please contact an administrator if this problem persists. Powered by PRN Asia 2011 PRN Asia
Dr Ivan Puah Shares 5 Beauty & Body Sculpting Trends In The Cosmetic & Aesthetic Industry For 2023
SINGAPORE, Dec. 1, 2022 /PRNewswire/ -- As we look forward to the new year, Dr Ivan Puah, Medical Director at Amaris B. Clinic, who has more than 15 years of medical aesthetics and surgical body contouring experience, shares five beauty and body sculpting trends expected to take centre stage in 2023. Dr Ivan Puah, Medical Director at...
LUCIDITY phase 3 topline data presented at CTAD for HMTM – the only oral anti-Tau therapy in late-stage development
- Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities - Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer's Disease (CTAD) conference on Wednesday, 30th November 2022, in San Francisco - For people with early Alzheimer's (MCI), HMTM improvement...
Menarini Group Presents Updated Results from Pivotal Phase 3 EMERALD Trial at the 2022 San Antonio Breast Cancer Symposium (SABCS) that Demonstrate Elacestrant’s PFS Increases with Duration of Prior...
Elacestrant demonstrated longer progression-free survival (PFS) vs SOC endocrine therapy with medians up to 8.6 months, positively associated with the duration of prior treatment with CDK4/6 inhibitors Elacestrant side effects were manageable and consistent with previously reported results Results demonstrate that elacestrant may have the potential to become a new standard of care as...
S3 Connected Health Receives Frost & Sullivan’s Award for Helping Medical Device Companies Create Custom Connected Medical Device Solutions
S3 Connected Health supports its partners and clients by defining optimal solutions that address their unique needs and constraints, taking customers from concept to development, operation, and lifecycle management SAN ANTONIO, Nov. 30, 2022 /PRNewswire/ -- Recently, Frost & Sullivan analyzed the global medical device connectivity industry and, based on its research findings, recognizes S3 Connected Health with the...
Prenetics Announces US$20 Million Stock Repurchase Program and Inclusion into the MSCI Global Micro Cap Index
LONDON and HONG KONG, Nov. 30, 2022 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced that its board of directors has authorized a share repurchase program, and that it has been included as a constituent stock in the MSCI Global Micro Cap Index (Hong Kong), with...
TIANGEN to Roll out a Stunning Automated Solution at Cell Bio 2022
WASHINGTON, Nov. 30, 2022 /PRNewswire/ -- TIANGEN, a leading brand in the field of nucleic acid purification in China, has announced its participation in the Cell Bio 2022, the joint meeting of the American Society for Cell Biology (ASCB) and European Molecular Biology Organization (EMBO), from December 4 to 6, in Washington, DC, where it will bring a groundbreaking...
Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor ASC40 for Acne
--To date, approximately 50% enrolled patients have completed 12-week treatment and all enrolled patients are expected to complete 12-week treatment by the end of February 2023 -- Clinical efficacy observed in patients who have completed 12-week treatment of ASC40 or placebo was comparable to that from two U.S. FDA approved acne drugs - WINLEVI® and TWYNEO® --In the...
